Spots Global Cancer Trial Database for Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
Official Title: A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma
Study ID: NCT03995706
Conditions
Interventions
Study Description
Brief Summary: Single center, non-randomized, Phase 0 study. Sacituzumab Govitecan given preoperatively, followed by craniotomy with surgery or biopsy of brain tumors (GBM and metastatic brain tumors from Breast) and intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
Contact Details
Name: Andrew Brenner, MD, PhD
Affiliation: University of Texas Health at San Antonio
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
